Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

References

• Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67
   PubMed Web of Science ®Google Scholar
• Fillit H, Hill JW, Futterman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam Med 2002;34:528-35
   PubMed Web of Science ®Google Scholar
• Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?. Int J Geriatr Psychiatry 2001;16:653-66
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease -- results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44
   PubMed Web of Science ®Google Scholar
• Mohs RC, Doody RS, Morris JC, et al.; “312” Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8
   PubMed Web of Science ®Google Scholar
• Winblad B, Engedal K, Soininen H, et al.; Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95
   Google Scholar
• Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-19
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001;57:2153]. Neurology 2001;57:613-20
   PubMed Web of Science ®Google Scholar
• Winblad B, Kilander L, Eriksson S, et al.; Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-65
   Google Scholar
• Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008;25:399-407
   PubMed Web of Science ®Google Scholar
• Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459-69
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
   PubMed Web of Science ®Google Scholar
• Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr 1992;4(Suppl 1):55-69
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association, 1994
   Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
   PubMed Web of Science ®Google Scholar
• Panisset M, Roudier M, Saxton J, et al. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-5
   PubMed Web of Science ®Google Scholar
• Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S51-6
   PubMedGoogle Scholar
• Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-21
   PubMed Web of Science ®Google Scholar
• Olin JT, Schneider LS, Doody RS, et al. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatry Neurol 1996;9:176-80
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services publication (ADM), 1976
   Google Scholar
• Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-9
   PubMed Web of Science ®Google Scholar
• Galasko DR, Schmitt FA, Jin S, et al. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease [abstract]. Neurobiol Aging 2000;21(Suppl 1):S168
   Google Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
   PubMed Web of Science ®Google Scholar
• Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48(Suppl):9-15
   PubMed Web of Science ®Google Scholar
• Quinn J, Moore M, Benson DF. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology 2002;58:433-7
   PubMed Web of Science ®Google Scholar
• Homma A, Nakamura Y, Kobune S, et al. Reliability study on the Japanese version of the Clinician's Interview-Based Impression of Change. Dement Geriatr Cogn Disord 2006;21:97-103
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
   PubMed Web of Science ®Google Scholar
• Helmer C, Pérès K, Letenneur L, et al. Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity. Dement Geriatr Cogn Disord 2006;22:87-94
   PubMed Web of Science ®Google Scholar
• Livingston, G, Katona C, Francois C, et al. Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer's disease in the U.K. Int Psychogeriatr 2006;18:527-38
   PubMed Web of Science ®Google Scholar
• Nadkarni N, Black S. Cognitive outcomes. In Rockwood K, Gautheir S, eds. Trial Designs and Outcomes in Dementia Therapeutic Research. Abingdon, UK: Taylor and Francis, 2006:85-112
   Google Scholar
• Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41
   PubMed Web of Science ®Google Scholar
• Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004;19:624-33
   PubMed Web of Science ®Google Scholar
• Galasko D, Schmitt F, Thomas R, et al. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 2005;11:446-53
   PubMed Web of Science ®Google Scholar
• Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 2006;10:417-29
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Jorge R, Mizrahi R, et al. A prospective longitudinal study of apathy in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006;77:8-11
   PubMed Web of Science ®Google Scholar
• Johannsen P, Salmon E, Hampel H et al.; AWARE Study Group. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. CNS Drugs 2006;20:311-25
   PubMed Web of Science ®Google Scholar
• Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-46
   PubMed Web of Science ®Google Scholar
• Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:243-9
   PubMed Web of Science ®Google Scholar
• Burns A, Bernabi R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomized, placebo-controlled, double-blind trial. Lancet Neurol 2009;8:39-47
   PubMed Web of Science ®Google Scholar